Chapter 32

Gillings School Directory, “Ralph S. Baric, PhD,” UNC Gillings School of Global Public Health.

Rowan Jacobsen, “Inside the Risky Bat-Virus Engineering that Links America to Wuhan,” MIT Technology Review, Jun. 29, 2021.

“Baric Named a 2019 UNC Distinguished Professor,” UNC Gillings School of Global Public Health, Jul. 1, 2019.

Ibid.

Ralph S. Baric et al., “Systematic Assembly of a Full-Length Infectious cDNA of Mouse Hepatitis Virus Strain A59,” Journal of Virology 76, no. 21 (2002): 11065-11078, doi: 10.1128/jvi.76.21.11065-11078.2002.

Baric et al., Methods and Compositions for Chimeric Coronavirus Spike Proteins, US Patent US9884895B2, filed Mar. 20, 2015 and issued Feb. 6, 2018.

“Bayh-Dole Act,” Drexel University, Apr. 28, 2020, accessed Jun. 23, 2023.

NIH RePORTER, “NIAID mRNA Patents and Awards,” NIH, accessed Jun. 23, 2023.

Alexander Tin, “Moderna Offers NIH Co-Ownership of COVID Vaccine Patent amid Dispute with Government,” CBS News, Nov. 15, 2021.

“Remdesivir, Developed through a UNC-Chapel Hill Partnership, Proves Effective against COVID-19 in NIAID Human Clinical Trials,” UNC Gillings School of Global Public Health, Apr. 29, 2020.

“Biomedical Research: Information on Federal Contributions to Remdesivir,” United States Government Accountability Office, Mar. 2021.

Peter J. Pitts, “Remdesivir and Federal March-In Rights,” Health Affairs Forefront, Apr. 30, 2021.

Carolina Alumni Review, “Promise of Remdesivir Focuses Anew on Baric Lab,” UNC General Alumni Association, Apr. 30, 2020.

Maggie Fox, Jamie Gumbrect, Holly Yan, and Betsy Klein, “FDA Will Reportedly Authorize Use of Remdesivir for Covid-19 after Trial Shows ‘positive effect’ on Recovery Time,” CNN Health, Apr. 30, 2020.

Angus Liu, “Chinese Firm Copies Gilead’s Remdesivir, the Most Promising Drug against the New Coronavirus,” Fierce Pharma, Feb. 12, 2020.

Sabue Mulangu, MD, Lori E. Dodd, PhD, Richard T. Davey, Jr., MD et al., “A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics,” NEJM 381 (2019): 2293-2303, doi: 10.1056/NEJMoa1910993.

Allison L Totura, and Sina Bavari, “Broad-Spectrum Coronavirus Antiviral Drug Discovery,” Expert Opinion on Drug Discovery 14, no. 4 (2009): 397-412, doi: 10.1080/17460441.2019.1581171.

Vineet Menachery, Mark Denison, Ralph Baric et al., “Broad-Spectrum Antiviral Gs-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses” Science Translational Medicine 9, no. 396 (2017): 5-6, doi: 10.1126/scitranslmed.aal3653. *Supplemental-S7: https://bit.ly/45MotPv.

Carolina Alumni Review, “Promise of Remdesivir Focuses Anew on Baric Lab,” UNC General Alumni Association, Apr. 30, 2020.

“WHO Recommends against the Use of Remdesivir in COVID-19 Patients,” World Health Organization, Nov. 20, 2020.

Christopher Rowland, “Government Researchers Changed Metric to Measure Coronavirus Drug Remdesivir During Clinical Trial,” Washington Post, May 1, 2020.

Katherine J. Wu and Gina Kolata, “Remdesivir Fails to Prevent Covid-19 Deaths in New Trial,” New York Times, Oct. 15, 2020.

WHO Solidarity Trial Consortium, “Repurposed Antiviral Drugs for Covid-19—Interim WHO Solidarity Trial Results,” NEJM 384 (2021): 497-511, doi: 10.1056/NEJMoa2023184.

Gilead, “Gilead’s Investigational Antiviral Remdesivir Receives US Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19,” press release, May 1, 2020.

Steven Nelson, “Dr. Fauci Praises Remdesivir after Breakthrough in Coronavirus Treatment,” New York Post, Apr. 29, 2022.

Tim Schwab, “While the Poor Get Sick, Bill Gates Just Gets Richer,” The Nation, Oct. 5, 2020.

“Committed Grants: University of North Carolina at Chapel Hill,” Bill & Melinda Gates Foundation, accessed Jul. 5, 2023.

“Curriculum Vitae: Ralph Baric,” University of North Carolina, 2016.

Robert F. Kennedy Jr., Private Interview with Dr. Francis Boyle.

“US-China Collaborative Biomedical Research Program,” NIAID, last rev. Dec. 23, 2015.